A clinical trial update dated August 25, 2026 reports the status of study NCT01519791. The trial is titled "A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis."
This is a Phase 3 study. According to the listing, the trial status is now marked as completed. The study evaluated certolizumab pegol combined with methotrexate in adults with early active rheumatoid arthritis who had not previously used DMARDs.
No efficacy or safety results are included in this update. The listing reflects only the change in trial status and the date recorded. This brief does not report or imply any outcome data beyond the completion status noted in the record.
Readers interested in background on fragment 176-191 can consult the compound overview for additional context.